Truncated Versions of Substance P and Neurokinin A Reveal Signaling Bias at Tachykinin Receptors
Progressively truncated substance P and neurokinin A analogs show altered signaling profiles at NK1 and NK2 receptors, challenging assumptions about peptide-receptor activity.
Quick Facts
What This Study Found
Truncated tachykinin analogs retain receptor activity but show altered signaling bias at NK1R and NK2R, with the shortest functional versions being SP(6-11) and NKA(5-10).
Key Numbers
12 SP analogs and 10 NKA analogs tested. SP(6-11) and NKA(5-10) shortest versions. Measured cAMP (Gs) and IP3 (Gq) accumulation via BRET assays at NK1R and NK2R.
How They Did This
In vitro receptor pharmacology study progressively truncating SP and NKA, testing signaling activity at NK1R and NK2R with free and acetylated N-terminal variants.
Why This Research Matters
Understanding how peptide length affects receptor signaling helps design drugs that activate beneficial pathways while avoiding harmful ones — key for developing safer tachykinin-based therapies.
The Bigger Picture
This work demonstrates that peptide fragments can have different therapeutic profiles than their parent molecules, opening doors for designing biased agonists from natural neuropeptides.
What This Study Doesn't Tell Us
In vitro study — signaling bias in cell assays may not directly predict in vivo pharmacological effects. Only two receptor subtypes were studied.
Questions This Raises
- ?Can truncated tachykinin analogs be developed as biased agonists for specific therapeutic applications?
- ?How does acetylation of the N-terminus affect receptor selectivity and signaling?
Trust & Context
- Key Stat:
- SP(6-11) still active Even the shortest truncated substance P fragment retained activity at NK1 receptors but with altered signaling bias
- Evidence Grade:
- In vitro receptor pharmacology study — rigorous for understanding receptor biology but therapeutic applications remain theoretical.
- Study Age:
- Published in 2025 in the Journal of Biological Chemistry.
- Original Title:
- Challenging activity and signaling bias in tachykinin NK1 and NK2 receptors by truncated neuropeptides.
- Published In:
- The Journal of biological chemistry, 301(6), 108522 (2025)
- Authors:
- Petersen, Jacob E(2), Pavlovskyi, Artem, Madsen, Jesper J(2), Schwartz, Thue W, Frimurer, Thomas M, Olsen, Ole H
- Database ID:
- RPEP-13033
Evidence Hierarchy
Frequently Asked Questions
What are tachykinins?
Tachykinins are a family of neuropeptides including substance P and neurokinin A that are involved in pain transmission, inflammation, and many other physiological processes. They work by activating NK1 and NK2 receptors.
What is signaling bias?
Signaling bias means a drug or peptide activates some pathways through a receptor more than others. This is important because different pathways can produce beneficial or harmful effects, so biased drugs could be safer than non-selective ones.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13033APA
Petersen, Jacob E; Pavlovskyi, Artem; Madsen, Jesper J; Schwartz, Thue W; Frimurer, Thomas M; Olsen, Ole H. (2025). Challenging activity and signaling bias in tachykinin NK1 and NK2 receptors by truncated neuropeptides.. The Journal of biological chemistry, 301(6), 108522. https://doi.org/10.1016/j.jbc.2025.108522
MLA
Petersen, Jacob E, et al. "Challenging activity and signaling bias in tachykinin NK1 and NK2 receptors by truncated neuropeptides.." The Journal of biological chemistry, 2025. https://doi.org/10.1016/j.jbc.2025.108522
RethinkPeptides
RethinkPeptides Research Database. "Challenging activity and signaling bias in tachykinin NK1 an..." RPEP-13033. Retrieved from https://rethinkpeptides.com/research/petersen-2025-challenging-activity-and-signaling
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.